NCT07217912View on ClinicalTrials.gov

Daridorexant to Prevent Post-cardiotomy Delirium

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Postoperative Cognitive DeclinePostoperative Delirium
Interventions
DRUG

Daridorexant 50 mg

Administered consistent with labeling from the US Food and Drug Administration.

OTHER

Placebo

Identical appearing to daridorexant

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT07217912 - Daridorexant to Prevent Post-cardiotomy Delirium | Biotech Hunter | Biotech Hunter